Skip to main content
. 2022 Nov 22;13:1011942. doi: 10.3389/fendo.2022.1011942

Table 1.

Clinical characteristic of the study groups.

Clinical Parameters NMS-LF–(n=22) NMS-LF+ (n=22) MS-LF- (n=21) MS-LF+ (n=23)
Age (years) 35 ± 15.3 37 ± 16.8 46 ± 11.5**b 48 ± 11.01
Sex (m/f) 13M/9F 12M/10F 11M/10F 9M/14F
TROPBIO 10.9 ± 18.9 3544.4 ± 7105.1*a 8.9 ± 3.1 4414.7 ± 8744.1*c
Waist (cm) 70 ± 10.7 78 ± 9.4**a 96 ± 11.7***b 93 ± 11.7
BMI (kg/m2) 19 ± 3.4 22 ± 3.9*** a 28 ± 5.2***b 25 ± 4.0
Systolic BP (mmHg) 110 ± 8.4 108 ± 13.1 140 ± 15.5***b 137 ± 21.1
Diastolic BP(mm Hg) 70 ± 9.1 70 ± 9.2 86 ± 10.2*** b 83 ± 14.2
FBS (mg/dl) 82 ± 5.6 86 ± 7.0 113 ± 35.6**b 126 ± 44.2
PGBS/PPBS 101 ± 30.5 115 ± 36.7 191 ± 76.4***b 224 ± 107.3
Glycated Haemoglobin (%) 5 ± 0.5 6 ± 0.4 7 ± 1.5***b 7 ± 1.7
Total Serum Cholesterol (mg/dl) 167 ± 22.7 178 ± 34.5 189 ± 34.8*b 212 ± 40.0*c
Serum triglycerides (mg/dl) 71 ± 32.7 96 ± 36.4* a 197 ± 6***b 185 ± 67.7
HDL-cholesterol (mg/dl) 51 ± 7.9 42 ± 8.1** a 38 ± 6.8***b 41 ± 8.3
LDL- cholesterol (mg/dl) 101 ± 21.5 117 ± 31.6* a 104 ± 40.0 134 ± 36.4** c
Microalbuminuria (mg/dl) 9 ± 1.6 7 ± 4.9 15 ± 22.4 24 ± 34.9
Urea 21 ± 6.4 22 ± 5.3 20 ± 4.3 22 ± 5.1
Creatinine 1 ± 0.2 1 ± 0.9 1 ± 0.1 1 ± 0.2
Diabetes status (%) NGT-95; PDM-5; NDM-0;KDM-0 NGT-77; PDM-23; NDM-0;KDM-0 NGT-14; PDM-62; NDM10; KDM-14 NGT-26; PDM-30; NDM-22;KDM-22
Hypertension (%)
Systolic BP 0 5 76 65
Diastolic BP 5 5 76 43
Central obesity (%) 5 23 81 78
Hypertriglyceridemia (%) 5 9 81 70
Dyslipidemia (%) 9 64 90 83

BMI, Body Mass Index; FBS, Fasting Blood Sugar; PGBS, Post Glucose Blood Sugar/PPBS, Post Prandial Blood Sugar; HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein.

a NMS-LF- vs NMS-LF+, b MS-LF- vs NMS-LF+ and c NMS-LF- vs MS-LF- groups were compared using Student t-test.

Data is shown as mean ± SD for continuous variables. Values highlighted in bold show significant difference.

* <0.05; ** <0.01; *** <0.001.